Brian Van Tine, MD, PhD
The investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) was active and well tolerated in patients with metastatic and nonresectable soft tissue sarcoma (STS), according to data from a single-arm phase II study presented at the 2016 Connective Tissue Oncology Society Annual Meeting.
Among 21 evaluable patients with locally advanced and/or metastatic intermediate or high-grade STS, GPX-150 induced a clinical benefit rate (CBR) of 43%. The CBR included 1 partial response and 8 patients with stable disease.
GPX-150 was well tolerated, detecting no irreversible cardiotoxicity and no grade 3 or 4 toxicities besides hematological toxicity. The toxicities included 2 patients (10%) with grade 3/4 neutropenia, 1 patient (5%) with grade 3 febrile neutropenia, and 3 patients (14%) with grade 3 anemia. The toxicities that were less than grade 3 included mucositis, nausea, vomiting, alopecia, and fatigue.